These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31927152)

  • 21. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.
    Li JZ; Gallien S; Do TD; Martin JN; Deeks S; Kuritzkes DR; Hatano H
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5998-6000. PubMed ID: 22890763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.
    Ryscavage P; Kelly S; Li JZ; Harrigan PR; Taiwo B
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3585-98. PubMed ID: 24733471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment.
    Navarro J; Caballero E; Curran A; Burgos J; Ocaña I; Falcó V; Torrella A; Pérez M; Ribera E; Crespo M
    Antivir Ther; 2016; 21(4):345-52. PubMed ID: 26756461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort.
    Elvstam O; Malmborn K; Elén S; Marrone G; García F; Zazzi M; Sönnerborg A; Böhm M; Seguin-Devaux C; Björkman P
    Clin Infect Dis; 2023 Jan; 76(1):25-31. PubMed ID: 36100984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study.
    Lombardi F; Bruzzesi E; Bouba YR; Di Carlo D; Costabile V; Ranzenigo M; Maggiolo F; Castagna A; Callegaro AP; Zoncada A; Paolucci S; Micheli V; Renica S; Bezencheck A; Rossetti B; Santoro MM
    AIDS Res Hum Retroviruses; 2024 Feb; 40(2):80-89. PubMed ID: 37345697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent Low-level Viremia Predicts Subsequent Virologic Failure: Is It Time to Change the Third 90?
    Esber A; Polyak C; Kiweewa F; Maswai J; Owuoth J; Maganga L; Adamu Y; Hickey PW; Ake JA; Crowell TA
    Clin Infect Dis; 2019 Aug; 69(5):805-812. PubMed ID: 30462188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of low-level viraemia on virological failure among Asian children with perinatally acquired HIV on first-line combination antiretroviral treatment: a multicentre, retrospective cohort study.
    Sudjaritruk T; Teeraananchai S; Kariminia A; Lapphra K; Kumarasamy N; Fong MS; Hansudewechakul R; Bunupuradah T; Ly PS; Nallusamy RA; Sohn AH; Sirisanthana V;
    J Int AIDS Soc; 2020 Jul; 23(7):e25550. PubMed ID: 32628816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Low-level Viremia on Treatment Outcomes During ART - Is it Time to Revise the Definition of Virological Failure?
    Poveda E; Crespo M
    AIDS Rev; 2018; 20(1):71-72. PubMed ID: 29628513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy.
    Hsu JY; Sun HY; Hsieh TW; Chang SY; Chuang YC; Huang YS; Hsiao CY; Su YC; Liu WC; Chang SF; Hung CC
    J Glob Antimicrob Resist; 2022 Jun; 29():7-16. PubMed ID: 35172201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
    Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
    Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure.
    Gonzalez-Serna A; Swenson LC; Watson B; Zhang W; Nohpal A; Auyeung K; Montaner JS; Harrigan PR
    Clin Microbiol Infect; 2016 Dec; 22(12):1004.e9-1004.e16. PubMed ID: 27585940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal cohort study.
    Lao X; Zhang H; Deng M; Li Q; Xiao Q; He L; Ma L; Song A; Liang X; Yu F; Zhao H; Zhang F
    BMC Infect Dis; 2024 Jan; 24(1):8. PubMed ID: 38166689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City, China.
    Liu J; Li C; Sun Y; Fu C; Wei S; Zhang X; Ma J; Zhao Q; Huo Y
    Sci Rep; 2024 May; 14(1):10620. PubMed ID: 38724547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: an observational study in a tertiary hospital in Northern Taiwan, 2017-19.
    Kao SW; Liu ZH; Wu TS; Ku SW; Tsai CL; Shie SS; Huang PY; Wu YM; Hsiao YH; Chen NY
    J Antimicrob Chemother; 2021 Feb; 76(3):722-728. PubMed ID: 33331635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 low-level viremia affects T cell activation rather than T cell development in school-age children, adolescents, and young adults during antiretroviral therapy.
    Han J; Mu W; Zhao H; Hao Y; Song C; Zhou H; Sun X; Li G; Dai G; Zhang Y; Zhang F; Zeng H
    Int J Infect Dis; 2020 Feb; 91():210-217. PubMed ID: 31821891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya.
    Kantor R; DeLong A; Schreier L; Reitsma M; Kemboi E; Orido M; Obonge S; Boinett R; Rono M; Emonyi W; Brooks K; Coetzer M; Buziba N; Hogan J; Diero L
    AIDS; 2018 Nov; 32(17):2485-2496. PubMed ID: 30134290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study.
    Hermans LE; Carmona S; Nijhuis M; Tempelman HA; Richman DD; Moorhouse M; Grobbee DE; Venter WDF; Wensing AMJ
    PLoS Med; 2020 Feb; 17(2):e1003037. PubMed ID: 32097428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study.
    Elvstam O; Marrone G; Medstrand P; Treutiger CJ; Sönnerborg A; Gisslén M; Björkman P
    Clin Infect Dis; 2021 Jun; 72(12):2079-2086. PubMed ID: 32271361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study.
    Leierer G; Grabmeier-Pfistershammer K; Steuer A; Geit M; Sarcletti M; Haas B; Kanatschnig M; Rappold M; Zangerle R; Ledergerber B; Taylor N;
    PLoS One; 2015; 10(11):e0142923. PubMed ID: 26566025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China.
    Liu P; You Y; Liao L; Feng Y; Shao Y; Xing H; Lan G; Li J; Ruan Y; Li D
    BMC Infect Dis; 2022 May; 22(1):426. PubMed ID: 35509014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.